EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	JIN-A02 Sensitive: C2 – Inclusion Criteria JIN-A02 Sensitive : C2	JIN-A02 Sensitive: C2 – Inclusion Criteria JIN-A02 Sensitive : C2
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3	osimertinib Resistant: C3 – Early Trials osimertinib Resistant : C3
EGFR C797S	Lung Cancer	EGFR C797S	Lung Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	olmutinib Resistant: C3 – Early Trials olmutinib Resistant : C3	olmutinib Resistant: C3 – Early Trials olmutinib Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	rociletinib Resistant: C3 – Early Trials rociletinib Resistant : C3	rociletinib Resistant: C3 – Early Trials rociletinib Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	WZ4002 Resistant: C3 – Early Trials WZ4002 Resistant : C3	WZ4002 Resistant: C3 – Early Trials WZ4002 Resistant : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3	cetuximab + brigatinib Sensitive: C3 – Early Trials cetuximab + brigatinib Sensitive : C3
EGFR C797S	Lung Adenocarcinoma	EGFR C797S	Lung Adenocarcinoma	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3	brigatinib Sensitive: C3 – Early Trials brigatinib Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	bevacizumab + afatinib Sensitive: C3 – Early Trials bevacizumab + afatinib Sensitive : C3	bevacizumab + afatinib Sensitive: C3 – Early Trials bevacizumab + afatinib Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	BBT-176 Sensitive: C3 – Early Trials BBT-176 Sensitive : C3	BBT-176 Sensitive: C3 – Early Trials BBT-176 Sensitive : C3
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
EGFR C797S	Lung Adenocarcinoma	EGFR C797S	Lung Adenocarcinoma	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4	osimertinib Resistant: C4 – Case Studies osimertinib Resistant : C4
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D	APG-1252 Sensitive: D – Preclinical APG-1252 Sensitive : D
EGFR C797S	Lung Adenocarcinoma	EGFR C797S	Lung Adenocarcinoma	Notch inhibitor + osimertinib Sensitive: D – Preclinical Notch inhibitor + osimertinib Sensitive : D	Notch inhibitor + osimertinib Sensitive: D – Preclinical Notch inhibitor + osimertinib Sensitive : D
EGFR C797S	Lung Cancer	EGFR C797S	Lung Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
EGFR C797S	Lung Cancer	EGFR C797S	Lung Cancer	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	OBX02-011 Sensitive: D – Preclinical OBX02-011 Sensitive : D	OBX02-011 Sensitive: D – Preclinical OBX02-011 Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	BLU-945 + BLU-701 Sensitive: D – Preclinical BLU-945 + BLU-701 Sensitive : D	BLU-945 + BLU-701 Sensitive: D – Preclinical BLU-945 + BLU-701 Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	GB263T Sensitive: D – Preclinical GB263T Sensitive : D	GB263T Sensitive: D – Preclinical GB263T Sensitive : D
EGFR C797S	Non Small Cell Lung Cancer	EGFR C797S	Non Small Cell Lung Cancer	TRX-221 Sensitive: D – Preclinical TRX-221 Sensitive : D	TRX-221 Sensitive: D – Preclinical TRX-221 Sensitive : D

EGFR C797S

Associations